331
Participants
Start Date
March 31, 2008
Primary Completion Date
July 31, 2010
Study Completion Date
July 31, 2010
Quetiapine Fumarate Extended- Release
Open-label seroquel XR tablets: On Day 1 Patients received 300 mg, on Day 2 600 mg, on Day 3 600-800 mg and between Day 4-168 400-800 mg Seroquel XR, according to clinical judgement of investigator. Dose changes were in 200 mg fixed doses. Investigational product (IP) was supplied in open label wallet blister cards and subjects were instructed to take the IP once daily in the evening.
Research Site, Garran
Research Site, Newcastle
Research Site, Brisbane
Research Site, Meadowbrook
Research Site, Dandenong
Research Site, Calgary
Research Site, Claresholm
Research Site, Red Deer
Research Site, Vancouver
Research Site, Victoria
Research Site, Miramichi
Research Site, St. John's
Research Site, Sydney
Research Site, Belleville
Research Site, Brantford
Research Site, Chatham
Research Site, Cornwall
Research Site, Greater Sudbury
Research Site, London
Research Site, Markham
Research Site, Mississauga
Research Site, Newmarket
Research Site, Oakville
Research Site, Orléans
Research Site, Toronto
Research Site, Windsor
Research Site, Gatineau
Research Site, Greenfield Park
Research Site, Montreal
Research Site, Québec
Research Site, Rouyn-Noranda
Research Site, Verdun
Research Site, Prince Albert
Research Site, Saskatoon
Research Site, Hong Kong
Research Site, Seoul
Lead Sponsor
AstraZeneca
INDUSTRY